Treatment with fostamatinib in patients with immune thrombocytopenia: Experience from the Andalusian region in Spain-The Fostasur Study.

Autor:	Jiménez-Bárcenas R; Hospital de la Serranía de Ronda, Málaga, Spain., García-Donas-Gabaldón G; Hospital Universitario Virgen Macarena, Sevilla, Spain., Campos-Álvarez RM; Hospital Universitario de Jerez de la Frontera, Cádiz, Spain., Fernández-Sánchez de Mora MC; Hospital Universitario Reina Sofía, Córdoba, Spain., Luis-Navarro J; Hospital de Riotinto, Huelva, Spain., Domínguez-Rodríguez JF; Hospital Universitario Juan Ramón Jiménez, Huelva, Spain., Nieto-Hernández MDM; Complejo Hospitalario de Jaén, Jaén, Spain., Sánchez-Bazán I; Hospital Regional Universitario de Málaga, Malaga, Spain., Yera-Cobo M; Hospital Puerta del Mar, Cádiz, Spain., Cardesa-Cabrera R; Hospital de la Merced de Osuna, Sevilla, Spain., Jiménez-Gonzalo FJ; Hospital de la Merced de Osuna, Sevilla, Spain., Ruiz-Cobo MA; Hospital de la Merced de Osuna, Sevilla, Spain., Caparrós-Miranda I; Hospital Virgen de la Victoria, Málaga, Spain., Entrena-Ureña L; Hospital Universitario Virgen de Las Nieves, Granada, Spain., Fernández Jiménez D; Hospital Universitario San Cecilio, Granada, Spain., Díaz-Canales D; Hospital de la Serranía de Ronda, Málaga, Spain., Moreno-Carrasco G; Hospital de la Serranía de Ronda, Málaga, Spain., Calderón-Cabrera C; Hospital Universitario Virgen del Rocío, Instituto de Biomedicina de Sevilla, Universidad de Sevilla, Sevilla, Spain., Núñez-Vázquez RJ; Hospital Universitario Virgen del Rocío, Instituto de Biomedicina de Sevilla, Universidad de Sevilla, Sevilla, Spain., Pedrote-Amador B; Hospital Universitario Virgen del Rocío, Instituto de Biomedicina de Sevilla, Universidad de Sevilla, Sevilla, Spain., Mingot-Castellano ME; Hospital Universitario Virgen del Rocío, Instituto de Biomedicina de Sevilla, Universidad de Sevilla, Sevilla, Spain.
Jazyk:	angličtina
Zdroj:	British journal of haematology [Br J Haematol] 2024 May; Vol. 204 (5), pp. 1977-1985. Date of Electronic Publication: 2024 Apr 03.
DOI:	10.1111/bjh.19443
Abstrakt:	Immune thrombocytopenia (ITP) is characterized by low platelet counts (PLTs) and an increased risk of bleeding. Fostamatinib, a spleen tyrosine kinase inhibitor, has been approved as a second-line treatment for ITP. Real-world data on fostamatinib are lacking. This observational, retrospective, multicentre study, conducted in the Andalusia region of Spain, evaluated 44 adult primary ITP patients (47.7% female; median age 58 years; newly diagnosed ITP 6.8%; persistent 13.6%; chronic 79.5%; median four prior treatments) after ≥ 4 weeks of fostamatinib therapy. The median PLT at the initiation of fostamatinib was 15 × 10 9 /L. Common reasons for starting fostamatinib were refractoriness or intolerance to prior therapy, oral medication preference, history of thrombosis and cardiovascular risk. Dosing was individualized based on efficacy and tolerance. After 2 weeks, global response rate was 56.8% (response and complete response). Response rates were 70.5%, 62.5% and 64% at 4 weeks, 12 weeks and at the end of the study respectively. Adverse events were mild, and no patients discontinued as a result. This real-world study demonstrated a response rate similar to fostamatinib as seen in the pivotal clinical trials while including newly diagnosed patients and allowing for individualized dosing. (© 2024 British Society for Haematology and John Wiley & Sons Ltd.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu Plný text